WallStreetZenWallStreetZen

NASDAQ: SPRO
Spero Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SPRO past revenue growth

How has SPRO's revenue growth performed historically?
Company
93.95%
Industry
149.51%
Market
17.15%
SPRO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SPRO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SPRO's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SPRO earnings and revenue history

Current Revenue
$103.8M
Current Earnings
$22.8M
Current Profit Margin
22%

SPRO Return on Equity

Current Company
32.6%
Current Industry
-63.5%
Current Market
188%
SPRO's Return on Equity (32.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SPRO announces earnings.

SPRO Return on Assets

Current Company
18.2%
Current Industry
2.9%
SPRO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SPRO Return on Capital Employed

Current Company
17.49%
Current Industry
19.5%
SPRO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SPRO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SPRO$103.78M$25.77M$22.81M+92.11%N/A
MRNS$30.99M-$125.31M-$141.41M+257.32%N/A
CUE$5.49M-$46.05M-$50.73M+36.88%N/A
BYSI$1.55MN/A-$27.51M+34.56%N/A
ANTX$0.00-$64.68M-$64.73MN/AN/A
View Top Biotech Stocks

SPRO earnings dates

Next earnings date
May 9, 2024

Spero Therapeutics Earnings & Revenue FAQ

What were SPRO's earnings last quarter?

On Invalid Date, Spero Therapeutics (NASDAQ: SPRO) reported Q4 2023 earnings per share (EPS) of $0.97, up 4.3% year over year. Total Spero Therapeutics earnings for the quarter were $51.19 million. In the same quarter last year, Spero Therapeutics's earnings per share (EPS) was $0.93.

If you're new to stock investing, here's how to buy Spero Therapeutics stock.

What was SPRO's earnings growth in the past year?

As of Q2 2024, Spero Therapeutics's earnings has grown year over year. Spero Therapeutics's earnings in the past year totalled $22.81 million.

What is SPRO's earnings date?

Spero Therapeutics's earnings date is Invalid Date. Add SPRO to your watchlist to be reminded of SPRO's next earnings announcement.

What was SPRO's revenue last quarter?

On Invalid Date, Spero Therapeutics (NASDAQ: SPRO) reported Q4 2023 revenue of $73.52 million up 54.98% year over year. In the same quarter last year, Spero Therapeutics's revenue was $47.44 million.

What was SPRO's revenue growth in the past year?

As of Q2 2024, Spero Therapeutics's revenue has grown 93.95% year over year. This is 55.56 percentage points lower than the US Biotechnology industry revenue growth rate of 149.51%. Spero Therapeutics's revenue in the past year totalled $103.78 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.